GEMPHARMATECH released its performance for the first three quarters, with a net profit attributable to the parent company of 110 million yuan, a year-on-year increase of 11.9%Zhitong·Oct 22, 2025 at 04:55 AM688046+3.83%
GEMPHARMATECH: Net profit in the first half of 2025 was 70.9055 million yuan, a year-on-year decrease of 7.12%Zhitong·Aug 22, 2025 at 04:51 AM688046+3.83%
The CRO sector rose, with JOINN up 8.94%, GEMPHARMATECH up 7.3%, Bide up 6.7%, and TIGERMED, Chemexpress, and Sun-Novo all rising over 5%Zhitong·Jun 29, 2025 at 10:15 PM603127+3.72%061270.00%
Overview of the lifting of restrictions on A-shares by Zhitong | April 25Zhitong·Apr 24, 2025 at 08:01 PM605566+3.47%688046+3.83%
GemPharmatech opens new biotech hub in San Diego, boosting research capabilities with lab and vivarium.Unusual Whales·Apr 17, 2025 at 12:22 PM688046+3.83%
GemPharmatech Significantly Expands U.S. Capabilities with New San Diego Biotech Hub Facilitybiopharmadive·Apr 17, 2025 at 12:01 PM688046+3.83%
GEMPHARMATECH's approximately 206 million restricted shares will be listed and circulated on April 25Zhitong·Apr 16, 2025 at 05:23 AM688046+3.83%
GEMPHARMATECH: Overseas business focuses on the delivery of efficacy reports, "reciprocal tariffs" have little impact on the companyZhitong·Apr 7, 2025 at 09:28 PM688046+3.83%
GEMPHARMATECH plans to launch an employee stock ownership plan in 2025Zhitong·Mar 24, 2025 at 08:05 AM688046+3.83%
GEMPHARMATECH plans to launch a stock appreciation rights incentive plan in 2025Zhitong·Mar 24, 2025 at 08:02 AM688046+3.83%
GEMPHARMATECH's net profit for the year 2024 is 116 million yuan, a year-on-year decrease of 27.14%Zhitong·Feb 27, 2025 at 04:23 AM688046+3.83%
The innovative drug sector is rising, and these concept stocks have received intensive research from institutions this yearZhitong·Feb 20, 2025 at 08:26 AM301230+8.38%688046+3.83%
